Does Spravato Help with Anxiety? Understanding This Breakthrough Treatment
August 10, 2025
For individuals struggling with treatment-resistant depression (TDR) who also experience anxiety symptoms, the search for effective relief can feel overwhelming.
Many have tried multiple medications and therapies, only to find limited success. While Spravato (Esketamine) represents a breakthrough in treating treatment-resistant depression, you may wonder: can Spravato therapy also help with anxiety?
Understanding the relationship between Spravato and anxiety requires exploring both the science behind this innovative treatment and the current clinical evidence supporting its use.
Key Takeaways
- Spravato works through a unique glutamate system mechanism: Unlike traditional antidepressants that target serotonin or norepinephrine, Spravato acts on NMDA receptors in the brain’s glutamate system, helping restore neural connections that depression may have damaged, which may explain improvements in co-occurring anxiety symptoms.
- Strict safety criteria must be met for treatment eligibility: Candidates for Spravato must have tried at least two antidepressants without significant relief and cannot have existing heart conditions, be pregnant or breastfeeding, have liver problems, or have certain brain conditions like intracerebral hemorrhage, requiring comprehensive medical evaluation before treatment.
- Emerging research shows promise for anxiety symptoms alongside depression: Clinical studies indicate that esketamine appears equally effective in patients with treatment-resistant depression regardless of whether they have baseline anxiety symptoms, and some patients report improvements in social anxiety and generalized anxiety when receiving treatment for depression.
- Spravato is not FDA-approved specifically for anxiety disorders: While Spravato has FDA approval for treatment-resistant depression and major depressive disorder with acute suicidal ideation, it has not received specific approval for anxiety disorders, though some healthcare providers may consider off-label use for patients with both conditions.
How Spravato Works
Spravato works differently from traditional antidepressants, which typically target serotonin, norepinephrine, or dopamine systems.
Instead, this breakthrough therapy acts on the brain’s NMDA receptors (N-methyl-D-aspartate receptors), part of the glutamate system. This unique mechanism allows Spravato to help restore neural connections that depression may have damaged, potentially offering relief where other treatments have failed. Both clinical trials and our patients have noticed a reduction in depressive symptoms after administering the Spravato nasal spray.
The treatment involves a nasal spray administered in a comfortable, clinical setting under the professional supervision of a healthcare provider. Patients remain in our serene, spa-like environment for observation following each session, ensuring both safety and peace of mind.
This different approach to neurotransmitter activity may explain why many patients experience improvements in mood symptoms, including anxiety, that commonly co-occur with depression. Here’s more info on how, specifically, Spravato helps with depression, if you want to learn more about this.
Spravato, Anxiety, and FDA Approval
Currently, the FDA has approved Spravato specifically for treatment-resistant depression in adults and depressive episodes in adults with major depressive disorder with acute suicidal ideation or behavior.
The FDA approval is based on extensive clinical trials demonstrating the medication’s safety and effectiveness for these specific conditions.
While Spravato has not received FDA approval specifically for anxiety disorders, clinical research has shown promising results for individuals whose depression is accompanied by anxiety symptoms. Research published in recent studies indicates that Esketamine appears equally effective in patients with treatment-resistant depression, whether they have baseline anxiety symptoms or not.
Off-Label Use
Some healthcare providers may prescribe FDA-approved medications for conditions beyond their specific approval when clinical evidence supports such use. This practice, known as off-label prescribing, is common and legal in medical practice.
For Spravato and anxiety, some mental health professionals may consider this approach for patients who have both treatment-resistant depression and significant anxiety symptoms.
However, any decision about off-label use should always be made in consultation with qualified healthcare providers who can assess your individual circumstances, medical history, and treatment goals.
The Benefits of Using Spravato for Anxiety
While research specifically targeting anxiety disorders remains limited, emerging evidence and empirical findings suggest potential benefits for anxiety symptoms, particularly when they occur alongside depression.
Generalized Anxiety Disorder
Individuals with generalized anxiety disorder often experience persistent, excessive worry about various life circumstances.
For those whose anxiety co-occurs with treatment-resistant depression, Spravato’s unique mechanism of action may offer relief for both conditions simultaneously.
The restoration of neural pathways that occurs with esketamine treatment may help reduce the chronic worry and physical symptoms associated with generalized anxiety.
Social Anxiety Disorder
Social anxiety disorder involves intense fear or anxiety in social situations, often significantly impacting daily functioning. When combined with depression, these symptoms can be particularly debilitating.
Some patients receiving Spravato for depression have reported improvements in their social anxiety symptoms, though more research is needed to establish definitive benefits.
Wondering if Spravato can work for you? Read more on our blog:
- Does Spravato help with depression?
- How long does Spravato last?
- What do you do during Spravato treatment?
- Can Spravato be taken at home?
- How does Spravato make you feel?
- Does ketamine therapy work for people with ADHD?
- Can ketamine treatment work for social anxiety?
Research Evidence: A Systematic Review Perspective
A comprehensive systematic review examining ketamine and its enantiomers in treating depressive and anxiety disorders provides valuable insights into this therapy’s potential.
The review found that while all Ketamine formulations show promise in treating depressive disorders, research on anxiety-specific benefits remains limited, with only a few small-scale studies available.
The research emphasizes that while Esketamine (the S-enantiomer of Ketamine found in Spravato) demonstrates clear benefits for depression, more large-scale, head-to-head studies are needed to fully understand the comparative effectiveness of different ketamine formulations for anxiety disorders. This scientific approach aligns with our commitment to evidence-based treatment at Marpa Minds.
Who Can Use Spravato?
Spravato is recommended as a treatment after a thorough risk evaluation and mitigation strategies have been put in place by healthcare professionals.
Unlike oral antidepressant medication, Spravato is ony administered in controlled, clinical settings. And unlike Ketamine infusion therapy (IV Ketamine), intranasal Esketamine is FDA-approved, which also makes it eligible to be covered by health insurance plans.
Spravato may be appropriate for individuals who meet specific criteria and safety requirements. More specifically, Spravato is only prescribed to patients who have been on at least two antidepressant drugs without significant relief.
To ensure your safety and optimize treatment outcomes, candidates for Spravato therapy should also:
- Not have existing heart conditions – The medication can affect blood pressure and heart rate, making careful cardiovascular screening essential before treatment begins.
- Not be pregnant – The safety of Spravato during pregnancy has not been established, and the medication is not recommended for pregnant individuals.
- Not be breastfeeding – Due to limited data on esketamine’s presence in breast milk, the medication is not recommended during breastfeeding.
- Not have liver problems – Since the liver processes medications, existing liver conditions may affect how your body handles Spravato, requiring careful evaluation.
- Not have brain problems like a history of intracerebral hemorrhage – Certain neurological conditions may create additional risks that need thorough assessment before treatment.
Our comprehensive evaluation process ensures that Spravato represents a safe and appropriate option for your specific circumstances. We handle all insurance verification and prior authorization requirements, removing administrative barriers so you can focus on your healing journey.
Finding Hope in Evidence-Based Treatment
While Spravato’s primary FDA approval focuses on treatment-resistant depression and Major Depressive Disorder, the emerging evidence regarding anxiety symptoms offers reason for cautious optimism. For individuals who have struggled with both depression and anxiety without finding adequate relief through traditional treatments, this breakthrough therapy may represent a new path forward.
At Marpa Minds, we understand the frustration of trying multiple treatments without success. Our specialized focus on Spravato therapy, combined with our serene, supportive environment, ensures you receive the highest quality care during your treatment journey.
Moreover, we coordinate with your insurance provider to minimize financial barriers and work closely with your existing mental health team to optimize your overall care.
If you’re considering whether the Spravato nasal spray might help address both your depression symptoms and anxiety symptoms, we encourage you to speak with our specialized team. Together, we can explore whether this FDA-approved breakthrough treatment represents the right next step in your path to wellness.
About Author
